Antivenin (Latrodectus mactans) (Equine)
Trade name: Black Widow Spider Antivenin
Animal productapproved
Approved
Feb 13, 1936
Clinical trial activity
2 trials · 5 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00657540)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- lactrodectus mactans venomImmunity, passive
lactrodectus mactans venom immunity, passive
Approval history
- approvedFeb 13, 1936
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS5VJA14972G ↗
- ChEMBLCHEMBL2108858 ↗
Also known as
- analatro
- antivenin
- antivenin (latrodectus mactans)
- antivenin (latrodectus mactans)
- widow spider species antivenin (latrodectus mactans)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04848714 | Phase 1 | Jul 1, 2021 | Avant Santé Research Center S.A. de C.V, Laboratorios Silanes S.A. de C.V., Rare Disease Therapeutics |
| NCT00657540 | Phase 3 | Aug 1, 2009 | Instituto Bioclon, Rare Disease Therapeutics, University of Colorado, Denver |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rare Disease Therapeutics | For profit | 2 | 0 | 2 | 2009 |
| Avant Santé Research Center S.A. de C.V | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Instituto Bioclon | For profit | 1 | 1 | 1 | 2009 |
| Laboratorios Silanes S.A. de C.V. | For profit | 1 | 1 | 1 | 2021 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1